NEW YORK (TheStreet) -- The stock market rally continued on Tuesday, with the S&P 500 climbing 0.5%. On CNBC's "Fast Money" TV show, the trading panel took a look at some of this week's important tech earnings, with Google (GOOGL), Netflix (NFLX - Get Report) and Intel (INTC - Get Report) all scheduled to report. 

Netflix will be an important report because it has been a leader in the market, said Guy Adami, managing director of stockmonster.com. He expects the company to report good results and trade up to $750. 

Despite receiving a relatively bearish downgrade, shares of Intel traded lower by just 0.25% on the session. After falling 18% on the year, maybe investors have priced in enough bad news, said Dan Nathan, co-founder and editor of riskreversal.com. Investors can buy the stock if earnings and guidance are decent, he added. 

Pete Najarian, co-founder of optionmonster.com and trademonster.com, said he sold Intel because it has traded so poorly this year. However, instead of leaning on technology stocks, he said the financial sector is more important right now because the group is currently leading the market higher. 

Karen Finerman, president of Metropolitan Capital Advisors, pointed out Google's interesting 7.25% rally over the past three days. This is an interesting rally for a stock that hasn't really moved much in the past year, she added. Finerman is hoping the company's new CFO will consider returning cash to shareholders. 

Martin Pyykkonen, managing director at Rosenblatt Securities, has a $600 price target on Google and is looking for the company to grow revenue by 15% this quarter to go along with "stable margins." The company still has room to make acquisitions, but Twitter (TWTR - Get Report) looks like an unlikely candidate. He also likes Facebook (FB - Get Report) and has a $100 price target on the stock. 

Google's YouTube has generated billions in revenue, but fails to generate any significant profits, Nathan said. If the company announces a buyback plan it will attract new investors. He pointed to Apple (AAPL - Get Report) to show how well a stock can do when shareholders start to embrace the company and its stock after such an announcement. 

It's good to see Google's management being more cost-conscious with their money, Najarian said. However, he thinks an acquisition would be a good way to generate growth. 

If a company -- Google or not -- is going to buy Twitter, it'll likely come at a much steeper price than the current $22.8 billion market cap, Najarian added.

If Twitter trades up to $40, investors who are long should take profits, Nathan said, adding that if the company's new CEO is an internal employee, investors will likely be disappointed. Investors can stay long Twitter with a stop-loss at $34.25, Adami said. 

Turning to biotech, shares of Receptos (RCPT) climbed 10% in after-hours trading on news Celgene (CELG - Get Report) will acquire the company for $7.3 billion or $232 per share. 

Celgene is hitting a new all-time high on the news, too, Adami pointed out. Celgene is the "gold standard" in biotech, followed by Amgen (AMGN - Get Report) and Gilead Sciences (GILD - Get Report), he added. Juno Therapeutics (JUNO) and Kite Pharma (KITE) are good companies, too. 

Nathan thinks the sector is overvalued, with rich M&A deals and high valuations. 

Finerman sticks to the exchange-traded funds such as the iShares Nasdaq Biotechnology ETF (IBB - Get Report), SPDR Biotech ETF (XBI - Get Report) and First Trust NYSE Arca Biotechnology Index ETF (FBT - Get Report) because it's too difficult to know the individual situations for each company when it comes to drug approvals, current treatments and future pipeline products. 

For their final trades, Najarian is buying Facebook and Nathan is selling Google. Finerman said to sell the SPDR S&P 500 ETF (SPY - Get Report) for portfolio protection and Adami is buying Zillow (Z - Get Report).

Follow TheStreet.com on Twitter and become a fan on Facebook.